BEVACIZUMAB 784 MG / 100 ML NS IVPB; BEVACIZUMAB 350 MG/100 ml NS IVPB; BEVACIZUMAB 425 MG/ 100 ml NS IVPB; BEVACIZUMAB 420 MG/100 ml 0.9% NACL IVPB; BEVACIZUMAB 556 mg/100 ml NS IVPB BEVACIZUMAB 330 MG / 100 ML NS IVPB; BEVACIZUMAB 790 MG / 100 ML NS IVPB; BEVACIZUMAB 470 MG / 100 ML NS IVPB; BEVACIZUMAB 758 MG / 100 ML NS IVPB; BEVACIZUMAB 690 MG / 100 ML NS IVPB BEVACIZUMAB 599 MG/100 ml NS IVPB; BEVACIZUMAB 1113 MG / 100 ML NS IVPB; BEVACIZUMAB 660 MG /100 ml NS IVPB; BEVACIZUMAB 590 MG / 100 ML NS IVPB; BEVACIZUMAB 620 MG / 100 ML NS IVPB BEVACIZUMAB 800 MG / 100 ML NS IVPB, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233
Published August 21, 2019 · Recall initiated: June 12, 2019
Summary
FDA records drug Class II recall D-1752-2019, published August 21, 2019 and initiated June 12, 2019. Recalling firm: Infusion Options, Inc.; Status: Terminated; Reported quantity: N/A; Lot: all lots within expiry. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Lack of Assurance of Sterility
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Infusion Options, Inc.
- Distributor
- NY only
- Lot
- all lots within expiry
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAAdcetris 96 MG/100 ML NS IVPB, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934,August 21, 2019
- FDADIPHENHYDRAMINE 25 MG/50 ML NS, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934,August 21, 2019
- FDADOCETAXEL 60 MG / 250 ml D5W IVPB; DOCETAXEL 71 MG/ 250 ML NS IVPB; DOCETAXEL 155 MG/ 250 ml NS IVPB;August 21, 2019
- FDAINJECTAFER 720 MG in 100 ml NS IVPB; INJECTAFER 210 MG in 100 ml NS IVPB, Rx Only, Infusion Options, Inc. 5924August 21, 2019
- FDAAVASTIN 630 MG / 100 ML 0.9% NACL IVPB; AVASTIN 2.5 mg/ 0.1ML Syringe; AVASTIN 587.5 MG/100 ML 0.9% NACL IVPB;August 21, 2019
- FDACARFILZOMIB 65 MG IN 50 ML D5W IVPB; CARFILZOMIB 75 MG IN 50 ML D5W IVPB; CARFILZOMIB 50 MG IN 50 ML D5W IVPB;August 21, 2019
Questions about this recall
Was BEVACIZUMAB 784 MG / 100 ML NS IVPB; BEVACIZUMAB 350 MG/100 ml NS IVPB; BEVACIZUMAB 425 MG/ 100 ml NS IVPB; BEVACIZUMAB 420 MG/100 ml 0.9% NACL IVPB; BEVACIZUMAB 556 mg/100 ml NS IVPB BEVACIZUMAB 330 MG / 100 ML NS IVPB; BEVACIZUMAB 790 MG / 100 ML NS IVPB; BEVACIZUMAB 470 MG / 100 ML NS IVPB; BEVACIZUMAB 758 MG / 100 ML NS IVPB; BEVACIZUMAB 690 MG / 100 ML NS IVPB BEVACIZUMAB 599 MG/100 ml NS IVPB; BEVACIZUMAB 1113 MG / 100 ML NS IVPB; BEVACIZUMAB 660 MG /100 ml NS IVPB; BEVACIZUMAB 590 MG / 100 ML NS IVPB; BEVACIZUMAB 620 MG / 100 ML NS IVPB BEVACIZUMAB 800 MG / 100 ML NS IVPB, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233 recalled?
Yes. FDA published recall D-1752-2019 on August 21, 2019. Reported hazard: Lack of Assurance of Sterility
What should I do if I have this product?
Voluntary: Firm initiated · Letter